Polycationic TLR7/8-2 Conjugates for Enhanced Cellular Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery methods for TLR7 agonists face challenges in penetrating tumor-protective niches and achieving cellular uptake into the endosomal compartment, limiting their effectiveness as anti-cancer agents.
Innovation Solution
Development of novel covalent conjugates of TLR7 and/or TLR8 agonists with TLR2 agonists that are polycationic at physiological pH, enabling complex formation with nucleic acids and enhanced cellular uptake, thereby inducing an immune response and facilitating gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery methods are used for TLR7 agonists, then the delivery system is simple, but the ability to penetrate tumor-protective niches and achieve cellular uptake is insufficient
Solution Approach 1:
The patent combines TLR7 agonist and TLR2 agonist into a single conjugated molecule, creating a dual-functional compound that can simultaneously engage both receptors. This merging of functions into one molecule improves cellular uptake and immune activation efficiency without requiring separate delivery systems for each agonist.
Solution Approach 2:
The conjugated molecule represents a composite structure combining two distinct agonist moieties (TLR7 and TLR2 ligands) into one hybrid molecule. This composite design enables the molecule to exhibit properties of both parent compounds, achieving enhanced cellular penetration and immune response activation that neither component could achieve alone.
2Reliability
If TLR7 agonists are used alone, then the treatment is simple, but the immune response activation is insufficient
Solution Approach 1:
The conjugated molecule merges TLR7 and TLR2 agonistic activities into a single compound, enabling simultaneous activation of both receptors. This dual-receptor engagement produces a synergistic immune response that is stronger than activation of either receptor alone, while maintaining a single-molecule simplicity.
Solution Approach 2:
The conjugated molecule serves multiple functions: it acts as both a TLR7 agonist and a TLR2 agonist, and additionally functions as a transfection agent capable of delivering nucleic acids into cells. This multi-functionality enhances immune response activation while providing additional therapeutic capabilities.
3Reliability
If polycationic conjugated molecules are used, then cellular uptake and immune activation are enhanced, but the molecular structure becomes more complex
Solution Approach 1:
The patent modifies the chemical parameters of the agonist molecules by introducing polycationic character through specific structural features. This parameter change (adding positive charge density) enables enhanced cellular uptake and endosomal escape without fundamentally altering the core agonist structures, maintaining relatively simple molecular frameworks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugated molecules effectively trigger a robust innate and adaptive immune response, enhancing anti-tumor activity by improving cellular uptake and immune activation, and can be used for gene therapy by introducing therapeutic genes into cells.
Implementation Method 1
By virtue of being polycationic, the molecules of the invention have the ability to form a complex with polyanionic molecules such as nucleic acids
Implementation Method 2
Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) expressed by diverse cell types that play an important role in both innate and adaptive immunity. TLRs are type I membrane proteins with distinct sub-cellular localization and recognize a range of highly conserved molecular structures present on microbial pathogens
Implementation Method 3
by virtue of being polycationic, the conjugated TLR agonists of the invention have improved uptake by targeted cells
Data Source
AI summary
A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II: